What Servier Canada does

Servier Canada Inc. is the Canadian operating subsidiary of Les Laboratoires Servier, an independent international pharmaceutical group governed by a nonprofit foundation. Founded in 1978 and headquartered in Laval, Quebec, the company employs approximately 52 people and sells 10 brand-name prescription medicines across four therapeutic areas: Oncology, Cardio-metabolism, Immuno-inflammation, and Neuroscience. The Canadian portfolio distributes 11.5 million boxes per year through traditional pharmaceutical wholesale channels to hospitals, pharmacies, and healthcare providers, with products not sold directly online.

The company's core technology focus is precision oncology through IDH (isocitrate dehydrogenase) mutation-targeting small molecules. VORANIGO (vorasidenib), approved by Health Canada in August 2024, is the first oral targeted therapy for Grade 2 IDH-mutant glioma in patients aged 12 and older, with Phase 3 INDIGO trial data showing more than doubled progression-free survival versus placebo. TIBSOVO (ivosidenib), approved in 2024, targets mutant IDH1 in newly diagnosed AML (in combination with azacitidine) and previously treated cholangiocarcinoma. The legacy portfolio includes cardiovascular products (COVERSYL, COVERSYL PLUS, VIACORAM, LANCORA), the diabetes treatment DIAMICRON MR, oncology injectables (ASPARLAS, FOLOTYN, ONCASPAR), and VENIXXA for chronic venous disease.

Servier Canada generates revenue through prescription pharmaceutical sales reimbursed via Canadian provincial drug formularies and private insurance plans. The go-to-market relies on field sales representatives engaging oncologists, hematologists, neuro-oncologists, and cardiologists, supplemented by healthcare professional digital platforms (MyServier.ca, servieroncologypro.ca, oncoportfolio.ca) and disease awareness campaigns. As a wholly owned subsidiary of a foundation-governed parent with 100% of profits reinvested, Servier Canada operates without external equity capital, prioritizing long-term therapeutic innovation over short-term financial returns.

Name

Servier Canada

Legal name

Servier Canada Inc.

Website

https://servier.ca

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

251–500 employees

Short description

Servier Canada is the Canadian subsidiary of independent pharmaceutical group Servier, employing approximately 52 people to commercialize 10 prescription medicines across oncology, cardio-metabolism, immuno-inflammation, and neuroscience. Its precision oncology franchise targets IDH-mutant cancers with VORANIGO and TIBSOVO.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Prescription pharmaceuticals
• Targeted oncology therapies
• Cardio-metabolic medicines
• IDH mutation inhibitors
• Specialty therapeutics

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Prescription Pharmaceutical Sales: Servier Canada generates revenue through the sale of prescription pharmaceutical products to healthcare providers, hospitals, pharmacies, and through public and private drug reimbursement programs across Canadian provinces. Products are distributed through traditional pharmaceutical channels and are not sold directly online.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Servier Canada develops, manufactures, and commercializes a portfolio of 10 brand-name prescription pharmaceutical products across four therapeutic areas: Oncology, Cardio-metabolism, Immuno-inflammation, and Neuroscience. The portfolio includes targeted oral oncology therapies such as VORANIGO (vorasidenib) for Grade 2 IDH-mutant glioma and TIBSOVO (ivosidenib) for IDH1-mutated AML and cholangiocarcinoma, as well as cardiovascular (COVERSYL, COVERSYL PLUS, VIACORAM, LANCORA), diabetes (DIAMICRON MR), oncology (ASPARLAS, FOLOTYN, ONCASPAR), and chronic venous disease (VENIXXA) products.

Product overview

Servier Canada is a pharmaceutical company offering a portfolio of prescription medicines across multiple therapeutic areas. The product portfolio includes: VORANIGO® (vorasidenib) for Grade 2 IDH-mutant glioma and TIBSOVO® (ivosidenib) for AML and cholangiocarcinoma (both targeting IDH mutations); ASPARLAS®, FOLOTYN®, and ONCASPAR® for oncology; cardiovascular treatments including COVERSYL®, COVERSYL PLUS®, VIACORAM®, and LANCORA™; diabetes medication DIAMICRON® MR; and VENIXXA™ for chronic venous disease. The company operates in four therapeutic areas: Oncology, Cardio metabolism, Immuno-inflammation, and Neuroscience. Servier Canada has approximately 52 employees and sells 11.5 million boxes per year with 10 brand-name medicines on the market.

Differentiator

Problem solved

Functional benefit

Brands

• MyServier: Healthcare professional platform providing medical information, product details, and educational resources.
• Servier Oncology Pro
• OncoPortfolio
• Venixxa

Products and services

• VORANIGO (vorasidenib) First oral targeted therapy approved in Canada for Grade 2 IDH-mutant glioma. Once-daily oral treatment for adults and pediatric patients aged 12+ following surgery, targeting mutant IDH1 and IDH2 enzymes present in low-grade gliomas. In Phase 3 INDIGO trial, more than doubled progression-free survival versus placebo.
• TIBSOVO (ivosidenib) Oral targeted therapy that inhibits the mutant IDH1 enzyme. Reduces levels of cancer-related substance and helps restore normal blood cell development. Approved in combination with azacitidine for adults with newly diagnosed AML with IDH1 mutation who are not eligible for intensive chemotherapy, and for previously treated IDH1-mutated cholangiocarcinoma.
• ASPARLAS (calaspargase pegol) Calaspargase pegol injection product for oncology treatment.
• COVERSYL (perindopril erbumine) Perindopril erbumine tablets for the treatment of hypertension and cardiovascular conditions.
• COVERSYL PLUS (perindopril erbumine / indapamide) Combination tablet of perindopril erbumine and indapamide for cardiovascular treatment.
• DIAMICRON MR (gliclazide modified-release) Modified-release gliclazide tablets for the treatment of type 2 diabetes.
• FOLOTYN (pralatrexate) Pralatrexate injection for oncology treatment.
• LANCORA (ivabradine) Ivabradine for cardiovascular treatment.
• ONCASPAR (pegaspargase) Pegaspargase injection for oncology treatment.
• VENIXXA (purified micronized flavonoid fraction) Purified micronized flavonoid fraction (FFPM) for the treatment of chronic venous disease and hemorrhoids. Dedicated website available at venixxa.ca.
• VIACORAM (perindopril arginine / amlodipine) Combination tablet of perindopril arginine and amlodipine for cardiovascular treatment.

Quantifiable outcome

• VORANIGO more than doubled progression-free survival versus placebo in Phase 3 INDIGO trial
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Ontario Ministry of HealthcoreStrategic or Co-development Partner · 27 February 2026Ontario became the first Canadian province to publicly reimburse VORANIGO under the FAST (Funding Accelerated for Specific Treatments) program. This partnership demonstrates how innovative access pathways can accelerate time to access for clinically urgent, life-altering conditions. Servier is collaborating with provinces and territories to support equitable access to VORANIGO across Canada.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Bristol-Myers Squibb Canada: BMS Canada's oncology/hematology franchise (including IDHIFA, a competing IDH1/IDH2 inhibitor) overlaps directly with Servier Canada's IDH-mutant oncology portfolio, though BMS is a much larger, broad-portfolio incumbent spanning immuno-oncology, hematology and cardiovascular.
• AstraZeneca Canada: AstraZeneca Canada operates a large oncology + cardiovascular + rare disease pharmaceutical franchise. Its targeted therapy pipeline (including AML and glioma programs) and provincial reimbursement infrastructure closely parallel Servier Canada's go-to-market model.
• Roche Canada: Roche Canada is a major oncology and specialty pharmaceuticals incumbent with deep targeted-therapy and hematology coverage, and a national reimbursement team comparable in shape to Servier Canada's — a direct analogue in oncology commercialization at scale.
• Novartis Pharmaceuticals Canada: Novartis Canada runs a similar specialty-pharma footprint in oncology, hematology, and cardiovascular with targeted small-molecule and biologic therapies, providing useful comparability on Canadian listing, pricing, and field-sales productivity for an independent subsidiary.
• Pfizer Canada: Pfizer Canada's broad pharmaceutical portfolio spans oncology, cardiovascular, and rare diseases, with comparable enterprise field-sales motion targeting oncologists, hematologists and provincial reimbursement authorities. A benchmark for at-scale independent-oncology-distribution operations in Canada.
• Bayer Canada: Bayer Canada operates a comparable specialty-pharmaceutical mix including oncology agents and cardiovascular products (e.g., hypertension franchise), with similar field-sales engagement to Canadian oncologists and provincial formularies — a meaningful comparator for portfolio cross-selling.
• Sanofi Canada: Sanofi Canada mirrors Servier Canada's therapeutic mix across oncology, cardio-metabolism and rare disease, and similarly leverages an international parent's R&D pipeline for local launches — a useful peer for understanding parent-subsidiary value transfer in Canada's pricing environment.
• Takeda Canada: Takeda Canada's oncology and rare disease franchise competes head-to-head with Servier for hematology and specialty-care attention, and its combination of plasma-derived therapies (ONCASPAR overlap with Servier's ASPARLAS/ONCASPAR) and targeted oncology launches offers strong peer comparability.

Direct peers

• Ipsen Biopharmaceuticals Canada: Ipsen Canada is a specialty oncology and neuroscience focused mid-size subsidiary (focus on targeted oncology, neuro-oncology and rare tumors) — the closest direct comparability to Servier Canada's boutique 52-employee precision-oncology operating model in Canada.
• Jazz Pharmaceuticals Canada: Jazz Pharmaceuticals Canada is a specialty pharma focused on oncology/hematology and rare diseases with a small Canadian team and a portfolio of high-priced targeted therapies, similar in scale and reimbursement-driven commercial model to Servier Canada.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/servier-canada

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Canada